Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. 2012

Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
Laboratory of Clinical Psychopharmacology, Beijing An Ding Hospital, Capital Medical University, China.

OBJECTIVE To develop a combined population pharmacokinetic model (PPK) to assess the magnitude and variability of exposure to both clozapine and its primary metabolite norclozapine in Chinese patients with refractory schizophrenia via sparse sampling with a focus on the effects of covariates on the pharmacokinetic parameters. METHODS Relevant patient concentration data (eg, demographic data, medication history, dosage regimen, time of last dose, sampling time, concentrations of clozapine and norclozapine, etc) were collected using a standardized data collection form. The demographic characteristics of the patients, including sex, age, weight, body surface area, smoking status, and information on concomitant medications as well as biochemical and hematological test results were recorded. Persons who had smoked 5 or more cigarettes per day within the last week were defined as smokers. The concentrations of clozapine and norclozapine were measured using a HPLC system equipped with a UV detector. PPK analysis was performed using NONMEM. Age, weight, sex, and smoking status were evaluated as main covariates. The model was internally validated using normalized prediction distribution errors. RESULTS A total of 809 clozapine concentration data sets and 808 norclozapine concentration data sets from 162 inpatients (74 males, 88 females) at multiple mental health sites in China were included. The one-compartment pharmacokinetic model with mixture error could best describe the concentration-time profiles of clozapine and norclozapine. The population-predicted clearance of clozapine and norclozapine in female nonsmokers were 21.9 and 32.7 L/h, respectively. The population-predicted volumes of distribution for clozapine and norclozapine were 526 and 624 L, respectively. Smoking was significantly associated with increases in the clearance (clozapine by 45%; norclozapine by 54.3%). The clearance was significantly greater in males than in females (clozapine by 20.8%; norclozapine by 24.2%). The clearance of clozapine and norclozapine did not differ significantly between Chinese patients and American patients. CONCLUSIONS Smoking and male were significantly associated with a lower exposure to clozapine and norclozapine due to higher clearance. This model can be used in individualized drug dosing and therapeutic drug monitoring.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
January 2019, BioMed research international,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
January 2011, Arzneimittel-Forschung,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
July 2022, The Australian and New Zealand journal of psychiatry,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
January 2018, EBioMedicine,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
April 2024, Therapeutic drug monitoring,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
May 2009, International clinical psychopharmacology,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
July 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
April 2006, Schizophrenia research,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
January 2022, Frontiers in pharmacology,
Li-jun Li, and De-wei Shang, and Wen-biao Li, and Wei Guo, and Xi-pei Wang, and Yu-peng Ren, and An-ning Li, and Pei-xin Fu, and Shuang-min Ji, and Wei Lu, and Chuan-yue Wang
October 2007, Drug development and industrial pharmacy,
Copied contents to your clipboard!